Skip to main content
. 2022 Apr 20;23(9):4556. doi: 10.3390/ijms23094556

Figure 2.

Figure 2

(A) GPR55/CEA mRNA ratio in lymph nodes from non-cancerous disease patients (control) and colon cancer patients in different TNM stages (Stage I–IV). (B) GPR55/CEA mRNA ratio in metastatic (H&E(+)) and non-metastatic (H&E(−)) lymph nodes. Red horizontal lines indicate median values. Dashed horizontal line shows clinical cutoff equal to 0.1481 GPR55 mRNA/CEA mRNA ratio and (n) number of lymph nodes. p-Values were calculated by Kruskal–Wallis non-parametric ANOVA, followed by post hoc Dunn’s test for multiple comparisons in (A) and by two-tailed Mann–Whitney test for comparison between expression levels in (B).